Member Info for marik

"Bloody hell Marik where did you come from? Finding all sorts of nuggets. Fair play."

@Oakleaf72 been in this company for a long time now, but haven't felt the urge to come to this website and post a lot. The website we must admit looks very good and the job links to the US are also very telling. The company has a full out US focus and is ready to go and the vacancies page shows that they are clearly expanding which they wouldn't be doing if they had negative news. Expanding the workforce at this stage is clearly an expression of growth and would require some foresight on part of Synairgen.

Everyone knows that this isn't an RNS, but it certainly provides a dominant view that the company are bullish and believe in the SNG001.

GLA

Also note as has been pointed out, I was unaware of this, that poster "AndOnThisDay" should be given credit for first sight and post:

AndOnThisDay, Today 15:57, Posts: 2, Price: 192.90, No Opinion, "https://www.synairgen.com/careers"

Interesting to see some of the statements on this thread :-O but we all know that Abingdon have expertise in the subject.

Big movement indeed.

SNG Open positions ALL in the US:

Head of Medical Affairs US-based, full-time, initially home-office based
Head of Alliance Management US, full time
Head of US Commercial Operations US-based, full-time, initially home-office based
Head of Commercial Finance US-based, full-time, initially home-office based
US Market Access Lead US-based, full-time, initially home-office based

GLA

https://www.synairgen.com/careers

"Oh wow ... a very new look to the company's website. https://www.synairgen.com/"

Beautiful! If Carlsberg did a treatment for covid, then this would be the website they would create.

This looks like substantial news is on the way. Could be tonight.

What I like is that those with an opinion on a subject without any expertise can, on bulletin board like this, provide a narrative that places a nice hue on the subject.

An over reaction by some PI's has led to the share price going well below market value. From the target price without AffiDX as per Trinity Delta note i.e. 227p that's a 3x from the current share price. News on the AVA6000 looks imminent.

As anyone with a reasonable understanding of molecular, will point out that the process of replacing the antibody is very straight forward. This is the bread and butter for Abingdon - they know what they are doing and have decades of experience.

https://www.trinitydelta.org/wp-content/uploads/2022/01/AVCT-Lighthouse-220110.pdf

"Avacta will work on replacing the antibody within the test to ensure that test performance with the Omicron variant is comparable to that demonstrated with other mutations."

Despite the pausing of sales for AffiDX, Trinity Delta still value the pre|CISION platforms as before (i.e. unaffected by the announcement). Even after removing the diagnostics arm for Avacta, it is still valued at 227p.

https://www.trinitydelta.org/wp-content/uploads/2022/01/AVCT-Lighthouse-220110.pdf

We continue to view the Therapeutics pipeline as the greater driver of long-term value; our £559m rNPV for the Affimer and pre|CISION platforms is unaffected by this announcement.

The general consensus amongst doctors is that vaccines should be taken.

I like your thinking @tc101

10-20% would be good ($20bn). I believe the assets in the ground are bigger and will be verified by the imminent JORC results. So a smaller percentage will be required for that target.

Just been talking to a doctor in the US and she is putting this down to inadequate vaccination - due mainly to anti-vax.

Recent news on how DeepVerge works.

https://www.yorkshirepost.co.uk/business/this-is-how-york-based-deepverge-is-helping-to-detect-toxins-in-the-drinking-water-at-the-beijing-2022-winter-olympics-3516893

You're looking at the wrong chart, should have gone to specsavers and then Waitrose for the chart.

Some good points alextak and up2myneck

I'm reading it as it is. His transcript is available. Richard Marsden states from data to availability we are talking just months. He didn't sugar coat it or downplay it. Which is very good news.

By using the term "availability" it implies post-production. We are also aware that production should be geared up already to 100k per month. Within this timeframe of months we have a) results, b) EUA and c) production, which provides major move upwards from early this year.

GLA

---------
Marik,
I think what RM was saying , due to all the drug applications ( made by others) it may be months before they were heard so to speak.Imo it maybe such an emergency submission may take presidence and yes brought forward. RM was being conservative
In his explanation.
I want this more than anyone but I think patience is required at this time.

The next move is looking like 53p as per (7th Dec 21). That's a 20% move with a few short stops on the way up.

Looks promising.

Thanks for the info. Should be a good interview.

The organisational chart is quite interesting and Richard has drawn it out (see his tweet below):

https://mobile.twitter.com/RichardDugdale3/status/1482650351597760513